Dezazepide is primarily investigated for its role as a cholecystokinin (CCK) receptor antagonist. It has been studied in the context of gastrointestinal disorders, particularly for its potential to reduce symptoms associated with conditions like irritable bowel syndrome (IBS) and functional dyspepsia. By blocking CCK receptors, dezazepide may help alleviate issues such as abdominal pain, bloating, and altered bowel movements. Additionally, it has been explored in research related to anxiety and panic disorders, as CCK is known to play a role in the regulation of anxiety responses. However, its clinical applications remain largely experimental, and further studies are needed to establish its efficacy and safety in therapeutic use.